JAC Advance Access originally published online on September 20, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2002) 50, 533-539
© 2002 The British Society for Antimicrobial Chemotherapy
AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin
1 Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow, 119992 Russia; 2 Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA
Received 22 January 2002; returned 15 May 2002; revised 11 July 2002; accepted 15 July 2002
Most integral endpoints of antimicrobial effect, including area between the control growth and time–kill curves (ABBC), area above the curve (AAC) and area under the time–kill curve (AUBC) are determined over a dosing interval (
), regardless of the actual effect duration. Unlike these -related endpoints, the intensity of antimicrobial effect (IE) considers the area between the control growth and time–kill curves from time zero to the time when bacterial counts on the regrowth curve achieve the same maximal numbers as in the absence of antibiotic, even if this time is greater than . Recently, important differences between ABBC–, AAC–, AUBC– and IE–AUC/MIC relationships were reported in single-dose simulations. The present study was designed to examine these relationships in multiple-dose simulations. A clinical isolate of Staphylococcus aureus was exposed to simulated pharmacokinetics of moxifloxacin (MIC = 0.37 mg/L) and levofloxacin (MIC = 0.6 mg/L), simulating three consecutive 24 h doses, which varied over a 32-fold range in the 24 h AUC/MIC ratio (AUC/MIC: 14–444 h and 15–484 h, respectively). The cumulative effect of each treatment was expressed by IE, determined from time zero to the time after the third dose when the effect could no longer be detected, and by ABBC, AAC and AUBC calculated over a 72 h period (i.e. over three dosing intervals). With all four endpoints, systematic AUC/MIC increase-induced changes in effect—an increase in IE, ABBC and AAC, or a decrease in AUBC—were observed and the log AUC/MIC–response curves were fitted by an Emax model. Using IE, the effects of moxifloxacin and levofloxacin could be distinguished over a wider range of AUC/MIC ratios than with ABBC and AUBC, whereas no differences between the fluoroquinolones could be seen based on the AAC–AUC/MIC curves. Although ABBC and AUBC were more descriptive than AAC, these two endpoints distinguished the fluoroquinolone effects only over a relatively narrow AUC/MIC range (
40–100 h), which includes therapeutically achievable values for levofloxacin but not for moxifloxacin. Similar limitations of the -related endpoints might be critical in comparative studies with other new fluoroquinolones where therapeutic AUC/MIC ratios are >100 h.
* Corresponding author. Tel: +7-095-245-0154; Fax: +7-095-245-0295; E-mail: firsov{at}dol.ru
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Homma, T. Hori, G. Sugimori, and Y. Yamano Pharmacodynamic Assessment Based on Mutant Prevention Concentrations of Fluoroquinolones To Prevent the Emergence of Resistant Mutants of Streptococcus pneumoniae Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3810 - 3815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Murillo, A. Domenech, A. Garcia, F. Tubau, C. Cabellos, F. Gudiol, and J. Ariza Efficacy of High Doses of Levofloxacin in Experimental Foreign-Body Infection by Methicillin-Susceptible Staphylococcus aureus Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4011 - 4017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Firsov, S. N. Vostrov, I. Yu. Lubenko, A. P. Arzamastsev, Y. A. Portnoy, and S. H. Zinner ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model J. Antimicrob. Chemother., July 1, 2004; 54(1): 178 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Zinner, I. Yu. Lubenko, D. Gilbert, K. Simmons, X. Zhao, K. Drlica, and A. A. Firsov Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing J. Antimicrob. Chemother., October 1, 2003; 52(4): 616 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J Schentag, A. K Meagher, and A. Forrest Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models Ann. Pharmacother., September 1, 2003; 37(9): 1287 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Firsov, S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus Antimicrob. Agents Chemother., May 1, 2003; 47(5): 1604 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Zelenitsky, R. E. Ariano, H. Iacovides, S. Sun, and G. K. M. Harding AUC0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model J. Antimicrob. Chemother., April 1, 2003; 51(4): 905 - 911. [Abstract] [Full Text] [PDF]
|
|